Brain Proteomics

271

[80] E. C. Santa Cruz, F. da Silva Zandonadi, W. Fontes, et al., “A pilot study

indicating the dysregulation of the complement and coagulation cas-

cades in treated schizophrenia and bipolar disorder patients,” Biochim-

ica Et Biophysica Acta (BBA)-Proteins and Proteomics, vol. 1869, no. 8,

p. 140657, 2021.

[81] C. Knöchel, J. Kniep, J. D. Cooper, et al., “Altered apolipoprotein c

expression in association with cognition impairments and hippocampus

volume in schizophrenia and bipolar disorder,” European archives of psy-

chiatry and clinical neuroscience, vol. 267, pp. 199–212, 2017.

[82] J. S. Cassoli, P. C. Guest, A. G. Santana, et al., “Employing pro-

teomics to unravel the molecular effects of antipsychotics and their role

in schizophrenia,” PROTEOMICS–Clinical Applications, vol. 10, no. 4,

pp. 442–455, 2016.

[83] S. Garcia-Rosa, B. S. Carvalho, P. C. Guest, et al., “Blood plasma pro-

teomic modulation induced by olanzapine and risperidone in schizophre-

nia patients,” Journal of proteomics, vol. 224, p. 103813, 2020.

[84] J. Kucera, K. Horska, P. Hruska, et

al., “Interacting effects of

the mam model of schizophrenia and antipsychotic treatment: Un-

targeted proteomics approach in adipose tissue,” Progress in Neuro-

Psychopharmacology and Biological Psychiatry, vol. 108, p. 110165, 2021.

[85] B. J. Smith, C. Brandão-Teles, G. S. Zuccoli, et al., “Protein succinylation

and malonylation as potential biomarkers in schizophrenia,” Journal of

Personalized Medicine, vol. 12, no. 9, p. 1408, 2022.

[86] J. D. Cooper, S. Ozcan, R. M. Gardner, et al., “Schizophrenia-risk and

urban birth are associated with proteomic changes in neonatal dried blood

spots,” Translational psychiatry, vol. 7, no. 12, p. 1290, 2017.